Certain Underwriters at Lloyd's, London v. Reproductive Genetics Institute

2018 IL App (1st) 170923, 103 N.E.3d 346
CourtAppellate Court of Illinois
DecidedMarch 9, 2018
Docket1-17-0923
StatusUnpublished
Cited by1 cases

This text of 2018 IL App (1st) 170923 (Certain Underwriters at Lloyd's, London v. Reproductive Genetics Institute) is published on Counsel Stack Legal Research, covering Appellate Court of Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Certain Underwriters at Lloyd's, London v. Reproductive Genetics Institute, 2018 IL App (1st) 170923, 103 N.E.3d 346 (Ill. Ct. App. 2018).

Opinion

JUSTICE CUNNINGHAM delivered the judgment of the court, with opinion.

¶ 1 Plaintiff-appellant, Certain Underwriters at Lloyd's, London (Lloyd's), appeals from the dismissal of its amended complaint, which sought contribution against the defendant-appellee, Reproductive Genetics Institute (Genetics Institute). On appeal, the plaintiff argues that the trial court improperly dismissed its complaint because neither the Joint Tortfeasor Contribution Act (Contribution Act) ( 740 ILCS 100/5 (West 2016) ) nor case law prohibits its contribution claim. For the following reasons, we affirm the judgment of the circuit court of Cook County.

¶ 2 BACKGROUND

¶ 3 This contribution claim arises from a settlement in an Oklahoma state court action against Lloyd's insured, The New England Cryogenic Center (NECC), a Massachusetts company that collects and sells human sperm. In 1999, NECC purchased the assets of Snake River Technology, d/b/a Rocky Mountain Cryobank (the Cryobank), a corporation in the business of fertility assistance through cryopreservation. Its principal place of business was Wyoming. The Cryobank sent sperm donor samples to the Genetics Institute, an Illinois corporation that conducts genetic testing, to determine if the sperm donation samples contained the delta-F508 mutation for cystic fibrosis. In 1992, the Genetics Institute sent a letter to the Cryobank, stating that certain sperm samples, including donor N-170, did not have the delta-F508 mutation. NECC's purchase of the Cryobank in 1999 included the purchase of donor N-170's sperm, which NECC later advertised as free of the delta-F508 mutation.

¶ 4 In 2009, NECC sold donor N-170's sperm to an Oklahoma couple, the Kretchmars. Donor N-170's sperm was fertilized with Mrs. Kretchmar's egg, and she gave birth to a child with cystic fibrosis. Testing later revealed that donor N-170 is a carrier of the delta-F508 cystic fibrosisgene mutation.

¶ 5 On October 21, 2011, the Kretchmars filed a lawsuit against NECC in Oklahoma state court, alleging that their child's cystic fibrosis was caused by the delta-F508 mutation in donor N-170's sperm. On July 5, 2012, the court in Oklahoma approved a settlement agreement reached between the Kretchmars and NECC. Lloyd's, as NECC's insurer, paid the settlement proceeds on behalf of NECC. The Genetics Institute was never made a party to the Oklahoma action.

¶ 6 On August 17, 2013, Lloyd's filed its initial complaint against the Genetics Institute in the circuit court of Cook County. The complaint sought to recover the settlement proceeds that Lloyd's had paid to settle the Kretchmar lawsuit in Oklahoma. The complaint had five counts: contribution *348 , negligence, negligent misrepresentation, breach of warranty of merchantability, and breach of warranty for a particular purpose. The Genetics Institute filed a motion to dismiss the complaint pursuant to section 2-615 of the Code of Civil Procedure (Code) ( 735 ILCS 5/2-615 (West 2012) ). The circuit court granted the motion and dismissed the complaint without prejudice.

¶ 7 On June 26, 2014, Lloyd's filed an amended complaint, repleading the counts for contribution, negligence, and negligent misrepresentation, but replaced the two warranty counts with one count for breach of express warranty. The Genetics Institute again filed a motion to dismiss the complaint, pursuant to sections 2-615 and 2-619 of the Code ( 735 ILCS 5/2-615, 2-619 (West 2014) ). Relying upon Laue v. Leifheit , 105 Ill. 2d 191 , 85 Ill.Dec. 340 , 473 N.E.2d 939 (1984), for the proposition that a claim for contribution must be asserted in the underlying lawsuit, the trial court granted the Genetics Institute's motion and dismissed the complaint in its entirety, with prejudice.

¶ 8 Lloyd's filed a motion to reconsider, arguing, inter alia , that neither the Contribution Act nor Laue applies when the underlying action is in a different jurisdiction. The trial court denied the motion as to the contribution claim, stating: "whether or not defendant may have been subject to jurisdiction in the Oklahoma litigation is not a factor in dismissal of these counts under the Laue doctrine." The trial court, however, granted the motion to reconsider its dismissal of the count for breach of express warranty. Lloyd's subsequently filed a second amended complaint, repleading the contribution claim, along with an amended count for breach of express warranty. Again, the Genetics Institute filed a motion to dismiss the complaint pursuant to section 2-615.

¶ 9 On March 22, 2017, the trial court granted the Genetics Institute's motion to dismiss the second amended complaint. Lloyd's then filed a notice of appeal, challenging the trial court's dismissal of its contribution claim. 1

¶ 10 ANALYSIS

¶ 11 We note that we have jurisdiction to review the trial court's final order dismissing the complaint, as the notice of appeal was timely filed. Ill. S. Ct. R. 301 (eff. Feb. 1, 1994); R. 303 (eff. Jan. 1, 2015).

¶ 12 Lloyd's asserts that the trial court erred by interpreting Laue to require that a claim for contribution must be brought in the underlying lawsuit, even when the underlying litigation commenced in a jurisdiction outside of Illinois. Lloyd's argues that neither case law nor the Contribution Act prohibit it from filing a contribution claim in a new action where the Genetics Institute was not subject to the jurisdiction of the court in the underlying action. Specifically, Lloyd's claims that Laue cannot apply to the facts of this case because the court in Oklahoma did not have personal jurisdiction over the Genetics Institute; thus, it was impossible for Lloyd's to have asserted its contribution claim against the Genetics Institute in the underlying lawsuit. Lloyd's further argues that public policy considerations support the filing of a separate contribution action in Illinois because there would be no additional burden, other than on Lloyd's itself, and there is no risk of inconsistent verdicts because there was a settlement in the underlying Oklahoma action.

*349 ¶ 13 A motion to dismiss brought pursuant to section 2-615 challenges the legal sufficiency of a complaint by alleging defects on its face. Alpha School Bus Co. v. Wagner , 391 Ill. App. 3d 722 , 735, 331 Ill.Dec. 378 ,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Certain Underwriters at Lloyd's, London v. Reproductive Genetics Institute
2018 IL App (1st) 170923 (Appellate Court of Illinois, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
2018 IL App (1st) 170923, 103 N.E.3d 346, Counsel Stack Legal Research, https://law.counselstack.com/opinion/certain-underwriters-at-lloyds-london-v-reproductive-genetics-institute-illappct-2018.